Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Caredx Inc. currently has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 5 actions are being reviewed by 5 distinct examiners, ensuring that each pending matter is handled by a different individual. The portfolio is also spread across 4 distinct art units, showing a high degree of technical variety for a small number of actions. This level of distribution means that the prosecution strategy must be highly customized for each individual case, as there is almost no overlap in personnel or departments.
HORLICK, KENNETH R is the busiest examiner, with 1 pending office action. Since there are 5 distinct examiners for 5 pending actions, the workload is perfectly distributed, and no single examiner has more influence than the others. The presence of 4 distinct art units for only 5 actions suggests that the company's biotechnology innovations are being evaluated across several different specialized departments at the patent office. Practitioners should be aware that with 5 different examiners and 4 different art units, the feedback received on one application is unlikely to be applicable to the others, requiring a broad and adaptable approach to the 5 pending actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| §101 + other | 3 (60%) |
| §103 only | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HORLICK, KENNETH R | 1 | 79.0% | +15.3% |
| SABOUR, GHAZAL | 1 | 34.2% | +35.0% |
| COVINGTON, AMANDA R | 1 | 21.5% | +28.1% |
| STUBBS, JOHN THOMAS | 1 | — | — |
| MINCHELLA, KAITLYN L | 1 | 26.4% | +21.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19243957 | SEQUENCE-BASED ANALYSIS OF NUCLEIC ACIDS IN MIXED SAMPLES | SABOUR, GHAZAL | — |
| 18328651 | SYSTEMS AND METHODS FOR PREDICTING TRANSPLANT REJECTION | COVINGTON, AMANDA R | — |
| 18141226 | SYSTEMS AND METHODS FOR CLASSIFYING THE STATUS OF A TRANSPLANT | STUBBS, JOHN THOMAS | — |
| 17773031 | METHOD FOR IDENTIFYING TRANSPLANT DONORS FOR A TRANSPLANT RECIPIENT | MINCHELLA, KAITLYN L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19308103 | METHODS AND SYSTEMS FOR PROCESSING CELL-FREE SAMPLES | HORLICK, KENNETH R | — |
| 19243957 | SEQUENCE-BASED ANALYSIS OF NUCLEIC ACIDS IN MIXED SAMPLES | SABOUR, GHAZAL | — |
| 18328651 | SYSTEMS AND METHODS FOR PREDICTING TRANSPLANT REJECTION | COVINGTON, AMANDA R | — |
| 17773031 | METHOD FOR IDENTIFYING TRANSPLANT DONORS FOR A TRANSPLANT RECIPIENT | MINCHELLA, KAITLYN L | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| 1681 | 1 |
| 3686 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19308103 | METHODS AND SYSTEMS FOR PROCESSING CELL-FREE SAMPLES | HORLICK, KENNETH R | 1681 | §103 | Final Rejection | — | Pending | Aug 22, 2025 |
| 19243957 | SEQUENCE-BASED ANALYSIS OF NUCLEIC ACIDS IN MIXED SAMPLES | SABOUR, GHAZAL | 1686 | §101§103Other | Final Rejection | — | Pending | Jun 20, 2025 |
| 18328651 | SYSTEMS AND METHODS FOR PREDICTING TRANSPLANT REJECTION | COVINGTON, AMANDA R | 3686 | §101 | Final Rejection | — | Pending | Jun 02, 2023 |
| 18141226 | SYSTEMS AND METHODS FOR CLASSIFYING THE STATUS OF A TRANSPLANT | STUBBS, JOHN THOMAS | 1686 | §101§102§103 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 17773031 | METHOD FOR IDENTIFYING TRANSPLANT DONORS FOR A TRANSPLANT RECIPIENT | MINCHELLA, KAITLYN L | 1685 | §101§103§112 | Final Rejection | — | Pending | Apr 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCaredx Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Kenneth R Horlick has the most, with 1 of Caredx Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
